Literature DB >> 34240699

An outbreak caused by the SARS-CoV-2 Delta (B.1.617.2) variant in a care home after partial vaccination with a single dose of the COVID-19 vaccine Vaxzevria, London, England, April 2021.

Sarah V Williams1, Amoolya Vusirikala1, Shamez N Ladhani1, Elena Fernandez Ruiz De Olano2, Nalini Iyanger2, Felicity Aiano1, Kelly Stoker1, Guduru Gopal Rao3, Laurence John3, Bharat Patel1, Nick Andrews1, Gavin Dabrera1, Mary Ramsay1, Kevin E Brown1, Jamie Lopez Bernal1, Vanessa Saliba1.   

Abstract

We investigated a COVID-19 outbreak of the SARS-CoV-2 Delta variant of concern in a London care home, where 8/21 residents and 14/21 staff had received a single dose of Vaxzevria (ChAdOx1-S; AstraZeneca) vaccine. We identified 24 SARS-CoV-2 infections (16 residents, 8 staff) among 40 individuals (19 residents, 21 staff); four (3 residents, 1 staff) were hospitalised, and none died. The attack rate after one vaccine dose was 35.7% (5/14) for staff and 81.3% (13/16) for residents.

Entities:  

Keywords:  B.1.617.2 variant; COVID-19; ChAdOx1 vaccine; Delta variant; SARS-CoV-2; Vaxzevria; care home outbreaks; vaccine effectiveness

Mesh:

Substances:

Year:  2021        PMID: 34240699     DOI: 10.2807/1560-7917.ES.2021.26.27.2100626

Source DB:  PubMed          Journal:  Euro Surveill        ISSN: 1025-496X


  19 in total

1.  COVID-19 in a region of Cameroon hit by armed conflict.

Authors:  Andreas Ateke Njoh; Eric Mboke; Shalom Tchokfe Ndoula; Hassan Ben Bachir; Raoul Nembot; Cornelius Chebo; Adidja Aman; Yauba Saidu
Journal:  Pan Afr Med J       Date:  2022-01-12

Review 2.  Biological Properties of SARS-CoV-2 Variants: Epidemiological Impact and Clinical Consequences.

Authors:  Reem Hoteit; Hadi M Yassine
Journal:  Vaccines (Basel)       Date:  2022-06-09

3.  Efficacy and Safety of MSC Cell Therapies for Hospitalized Patients with COVID-19: A Systematic Review and Meta-Analysis.

Authors:  Wenchun Qu; Zhen Wang; Erica Engelberg-Cook; Dan Yan; Abu Bakar Siddik; Guojun Bu; Julie G Allickson; Eva Kubrova; Arnold I Caplan; Joshua M Hare; Camillo Ricordi; Carl J Pepine; Joanne Kurtzberg; Jorge M Pascual; Jorge M Mallea; Ricardo L Rodriguez; Tarek Nayfeh; Samer Saadi; Ravindra V Durvasula; Elaine M Richards; Keith March; Fred P Sanfilippo
Journal:  Stem Cells Transl Med       Date:  2022-07-20       Impact factor: 7.655

4.  Genomic Surveillance Tracks the First Community Outbreak of the SARS-CoV-2 Delta (B.1.617.2) Variant in Brazil.

Authors:  Alessandra P Lamarca; Luiz G P de Almeida; Ronaldo da Silva Francisco; Liliane Cavalcante; Douglas Terra Machado; Otávio Brustolini; Alexandra L Gerber; Ana Paula de C Guimarães; Cintia Policarpo; Gleidson da Silva de Oliveira; Lidia Theodoro Boullosa; Isabelle Vasconcellos de Souza; Erika Martins de Carvalho; Mario Sergio Ribeiro; Silvia Carvalho; Flávio Dias da Silva; Marcio Henrique de Oliveira Garcia; Leandro Magalhães de Souza; Cristiane Gomes Da Silva; Caio Luiz Pereira Ribeiro; Andréa Cony Cavalcanti; Claudia Maria Braga de Mello; Amilcar Tanuri; Ana Tereza R Vasconcelos
Journal:  J Virol       Date:  2021-11-03       Impact factor: 5.103

Review 5.  Molecular Evolution of Severe Acute Respiratory Syndrome Coronavirus 2: Hazardous and More Hazardous Strains Behind the Coronavirus Disease 2019 Pandemic and Their Targeting by Drugs and Vaccines.

Authors:  Hardeep Singh Tuli; Katrin Sak; Poonam Aggarwal; Ashif Iqubal; Sushil K Upadhaya; Jagjit Kaur; Ginpreet Kaur; Diwakar Aggarwal
Journal:  Front Cell Infect Microbiol       Date:  2021-12-14       Impact factor: 5.293

6.  Public Perceptions and Acceptance of COVID-19 Booster Vaccination in China: A Cross-Sectional Study.

Authors:  Xiaozhen Lai; He Zhu; Jiahao Wang; Yingzhe Huang; Rize Jing; Yun Lyu; Haijun Zhang; Huangyufei Feng; Jia Guo; Hai Fang
Journal:  Vaccines (Basel)       Date:  2021-12-10

7.  Mapping cross-variant neutralizing sites on the SARS-CoV-2 spike protein.

Authors:  Shiqi Xu; Yifan Wang; Yanxing Wang; Chao Zhang; Qin Hong; Chenjian Gu; Rong Xu; Tingfeng Wang; Yong Yang; Jinkai Zang; Yu Zhou; Zuyang Li; Qixing Liu; Bingjie Zhou; Lulu Bai; Yuanfei Zhu; Qiang Deng; Haikun Wang; Dimitri Lavillette; Gary Wong; Youhua Xie; Yao Cong; Zhong Huang
Journal:  Emerg Microbes Infect       Date:  2022-12       Impact factor: 7.163

8.  Simulation of future COVID-19 epidemic by vaccination coverage scenarios in Japan.

Authors:  Yuki Furuse
Journal:  J Glob Health       Date:  2021-11-30       Impact factor: 4.413

9.  SARS-CoV-2 antibody and T cell responses one year after COVID-19 and the booster effect of vaccination: A prospective cohort study.

Authors:  Willem A Mak; Johannes G M Koeleman; Marijke van der Vliet; Frans Keuren; David S Y Ong
Journal:  J Infect       Date:  2021-12-09       Impact factor: 6.072

Review 10.  Implication of the emergence of the delta (B.1.617.2) variants on vaccine effectiveness.

Authors:  Jaffar A Al-Tawfiq; Thoyaja Koritala; Saad Alhumaid; Mazin Barry; Abeer N Alshukairi; Mohamad-Hani Temsah; Abbas Al Mutair; Ali Rabaan; Raghavendra Tirupathi; Philippe Gautret
Journal:  Infection       Date:  2022-02-03       Impact factor: 7.455

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.